Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.
Bibliographical noteFunding Information:
This research was supported by Bio & Medical Technology Development Program Grants (2017M3A9D8063317) and a Mid-Career Researcher Program grant (2017R1A2B4002203) provided by the National Research (NRF) funded by the Ministry of Science, Information and Communication Technologies (ICT), and Future Planning, Republic of Korea. Additionally, this research was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A101032), National Research Foundation of Korea Grant funded by the Korea Government (MSIP, South Korea) (No.2015R1A2A2A01003829) and was also supported by a Korea University grant and the BK21 Plus Program (School of Life Sciences and Biotechnology, Korea University).
© 2018 by the The Korean Society for Biochemistry and Molecular Biology.
- Leukotriene B4 receptor-2
- Triple-negative breast cancer
ASJC Scopus subject areas
- Molecular Biology